.- I Introduction
.- 1 Antibody-Drug Conjugates: A Historical Review (Wei-Chiang Shen)
.- II The ADC Construct
.- 2 Payloads of Antibody-Drug Conjugates (Chalet Tan)
.- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy (Michael Ritchie, Laird Bloom, Gregory Carven, and Puja Sapra)
.- 4 Linker Design for Antibody-Drug Conjugates (E. Erica Hong and Ravi Chari)
.- III Development Issues
.- 5 Formulation Development for Antibody-Drug Conjugates (Junyan A. Ji, Jun Liu, Y. John Wang)
.- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates (Chen Xie and Zhijun Wang)
.- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates (Siddharth Sukumaran and Kedan Lin)
.- 8 Regulatory Considerations (Karen J. Cha)
.- IV Landscape, IP and Pharmacoeconomics
.- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy (Jeffrey Wang and Jonathan H. Watanabe)
.- V Case Studies
.- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal (Jennica L. Zaro)
.- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate (Bruce W. Hart Jr.)
.- 12 Ado-Trastuzumab Emtansine (Yun Luo, J?r?me J. Lacroix and Sunil Prabhu)
.- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer (Nancy Chan and Linda T. Vahdat)
.- VI From Today to Tomorrow
.- 14 Summary and Future Directions (Jennica L. Zaro, Jeffery Wang and Wei-Chiang Shen).
Related Subjects
Medical Medical Books Science Science & Math Science & Scientists Science & Technology